Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus : Results of a multicenter randomized, double-blind, placebo-controlled trial
β Scribed by Michelle A. Petri; Philip J. Mease; Joan T. Merrill; Robert G. Lahita; Mark J. Iannini; David E. Yocum; Ellen M. Ginzler; Robert S. Katz; Oscar S. Gluck; Mark C. Genovese; Ronald Van Vollenhoven; Kenneth C. Kalunian; Susan Manzi; Maria W. Greenwald; Jill P. Buyon; Nancy J. Olsen; Michael H. Schiff; Arthur F. Kavanaugh; Jacques R. Caldwell; Rosalind Ramsey-Goldman; E. William St. Clair; Allan L. Goldman; Rita M. Egan; Richard P. Polisson; Kevin G. Moder; Naomi F. Rothfield; Robert T. Spencer; Kathryn Hobbs; Barri J. Fessler; Leonard H. Calabrese; Larry W. Moreland; Stanley B. Cohen; Betty J. Quarles; Vibeke Strand; Marc Gurwith; Kenneth E. Schwartz
- Book ID
- 118282128
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 156 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). ## Methods Patients with a Safety of Estrogens in Lupus Erythematosus: National